Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.

@article{Weeda2013FibrolamellarVO,
  title={Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.},
  author={V B Weeda and Maciej Murawski and Amanda Jayne McCabe and Rudolf Maibach and Laurence Brugi{\`e}res and Derek Roebuck and Monique Fabre and Arthur Zimmermann and Jean Bernard Otte and Michael V. Sullivan and Giorgio Perilongo and Margaret Childs and Penelope Brock and Joszef Zsiros and Jack Plaschkes and Piotra Czauderna and D C Aronson},
  journal={European journal of cancer},
  year={2013},
  volume={49 12},
  pages={2698-704}
}
PURPOSE Fibrolamellar hepatocellular carcinoma (FL-HCC) and conventional hepatocellular carcinoma (HCC) cases in two consecutive paediatric HCC trials were analysed to compare outcome and derive treatment implications. PATIENTS AND METHODS Data of 24 FL-HCC (24% PRETEXT IV) and 38 HCC (42% PRETEXT IV) cases from SIOPEL-2 and -3 (1995-1998, 1998-2006) were analysed. Patients were treated according to SIOPEL-2 and -3 high-risk protocol (carboplatin+doxorubicin alternating with cisplatin; seven… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…